158 related articles for article (PubMed ID: 10597398)
1. Helicobacter pylori vaccine development and use: a cost-effectiveness analysis using the Institute of Medicine Methodology.
Rupnow MF; Owens DK; Shachter R; Parsonnet J
Helicobacter; 1999 Dec; 4(4):272-80. PubMed ID: 10597398
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of a potential prophylactic Helicobacter pylori vaccine in the United States.
Rupnow MF; Chang AH; Shachter RD; Owens DK; Parsonnet J
J Infect Dis; 2009 Oct; 200(8):1311-7. PubMed ID: 19751153
[TBL] [Abstract][Full Text] [Related]
3. Quantifying the population impact of a prophylactic Helicobacter pylori vaccine.
Rupnow MF; Shachter RD; Owens DK; Parsonnet J
Vaccine; 2001 Dec; 20(5-6):879-85. PubMed ID: 11738753
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of a potential future Helicobacter pylori vaccine in the Netherlands: the impact of varying the discount rate for health.
de Vries R; Klok RM; Brouwers JR; Postma MJ
Vaccine; 2009 Feb; 27(6):846-52. PubMed ID: 19084566
[TBL] [Abstract][Full Text] [Related]
5. Identification of Helicobacter pylori and the evolution of an efficacious childhood vaccine to protect against gastritis and peptic ulcer disease.
Blanchard TG; Czinn SJ
Pediatr Res; 2017 Jan; 81(1-2):170-176. PubMed ID: 27701380
[TBL] [Abstract][Full Text] [Related]
6. How far are we from vaccination against Helicobacter pylori infection?
Stubljar D; Jukic T; Ihan A
Expert Rev Vaccines; 2018 Oct; 17(10):935-945. PubMed ID: 30238819
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of screen-and-treat strategy in asymptomatic Chinese for preventing Helicobacter pylori-associated diseases.
Chen Q; Liang X; Long X; Yu L; Liu W; Lu H
Helicobacter; 2019 Apr; 24(2):e12563. PubMed ID: 30672082
[TBL] [Abstract][Full Text] [Related]
8. Efficacy, safety, and immunogenicity of an oral recombinant Helicobacter pylori vaccine in children in China: a randomised, double-blind, placebo-controlled, phase 3 trial.
Zeng M; Mao XH; Li JX; Tong WD; Wang B; Zhang YJ; Guo G; Zhao ZJ; Li L; Wu DL; Lu DS; Tan ZM; Liang HY; Wu C; Li DH; Luo P; Zeng H; Zhang WJ; Zhang JY; Guo BT; Zhu FC; Zou QM
Lancet; 2015 Oct; 386(10002):1457-64. PubMed ID: 26142048
[TBL] [Abstract][Full Text] [Related]
9. [-Development of a mouse model for Helicobacter pylori infection in the human--progress toward vaccination against ulcer disease?-].
Gallwitz B; Schmidt WE
Z Gastroenterol; 1996 Mar; 34(3):202-4. PubMed ID: 8650975
[No Abstract] [Full Text] [Related]
10. Exploring novel vaccines against Helicobacter pylori: protective and therapeutic immunization.
Vyas SP; Sihorkar V
J Clin Pharm Ther; 1999 Aug; 24(4):259-72. PubMed ID: 10475984
[TBL] [Abstract][Full Text] [Related]
11. New vaccines against otitis media: projected benefits and cost-effectiveness.
O'Brien MA; Prosser LA; Paradise JL; Ray GT; Kulldorff M; Kurs-Lasky M; Hinrichsen VL; Mehta J; Colborn DK; Lieu TA
Pediatrics; 2009 Jun; 123(6):1452-63. PubMed ID: 19482754
[TBL] [Abstract][Full Text] [Related]
12. Helicobacter pylori vaccine strategies--triggering a gut reaction.
Hatzifoti C; Wren BW; Morrow WJ
Immunol Today; 2000 Dec; 21(12):615-9. PubMed ID: 11114421
[TBL] [Abstract][Full Text] [Related]
13. Prospects for the development of a vaccine against Helicobacter pylori.
Telford JL; Ghiara P
Drugs; 1996 Dec; 52(6):799-804. PubMed ID: 8957151
[TBL] [Abstract][Full Text] [Related]
14. Status of vaccine research and development for Helicobacter pylori.
Sutton P; Boag JM
Vaccine; 2019 Nov; 37(50):7295-7299. PubMed ID: 29627231
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of pneumococcal conjugate vaccination in Croatia.
Vučina VV; Filipović SK; Kožnjak N; Stamenić V; Clark AD; Mounaud B; Blau J; Hoestlandt C; Kaić B
Vaccine; 2015 May; 33 Suppl 1():A209-18. PubMed ID: 25919163
[TBL] [Abstract][Full Text] [Related]
16. Helicobacter pylori vaccine: from past to future.
Agarwal K; Agarwal S
Mayo Clin Proc; 2008 Feb; 83(2):169-75. PubMed ID: 18241627
[TBL] [Abstract][Full Text] [Related]
17. A novel chimeric flagellum fused with the multi-epitope vaccine CTB-UE prevents Helicobacter pylori-induced gastric cancer in a BALB/c mouse model.
Song H; Lv X; Yang J; Liu W; Yang H; Xi T; Xing Y
Appl Microbiol Biotechnol; 2015 Nov; 99(22):9495-502. PubMed ID: 26062531
[TBL] [Abstract][Full Text] [Related]
18. Respiratory syncytial virus immunization program for the United States: impact of performance determinants of a theoretical vaccine.
Régnier SA
Vaccine; 2013 Sep; 31(40):4347-54. PubMed ID: 23896421
[TBL] [Abstract][Full Text] [Related]
19. Is there a rationale for eradication of Helicobacter pylori? Cost-benefit: the case for.
Moayyedi P; Axon AT
Br Med Bull; 1998; 54(1):243-50. PubMed ID: 9604447
[TBL] [Abstract][Full Text] [Related]
20. Immunology and vaccines and nanovaccines for Helicobacter pylori infection.
Milani M; Sharifi Y; Rahmati-Yamchi M; Somi MH; Akbarzadeh A
Expert Rev Vaccines; 2015 Jun; 14(6):833-40. PubMed ID: 25645086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
